Neurosurgery Watch

Stay up to date with the latest clinical findings in Neurosurgery Watch. Each month, our panel identifies and summarizes key points of selected significant papers from over 50 journals. We emphasize the most significant findings that potentially change clinical management or treatment of neurological diseases.

Please contact us with any suggestions or comments.

John S. Kuo, MD PhD FACS
Austin, Texas
Co-Editor
Robert Starke, MD MSc
Miami, Florida 
Co-Editor
Search Neurosurgery Watch

Three Clinical Trials of Endovascular Therapy for Ischemic Stroke

August 1, 2013
By: 
Alexander A. Khalessi, MD

Editor’s note: The CNS, AANS, SVIN, SNIS & ASNR-endorsed joint response to these 3 clinical trials is available at Neurosurgery®.

IMS III was a randomized controlled clinical trial involving 656 iv-tPA eligible participants with presenting NIH Stroke Scales greater than 8....

CV
PA

Headaches After Craniotomy Versus Endovascular Therapy for Aneurysms

August 1, 2013
Cerebrovascular, Pain
By: 
Justin F. Fraser, MD
Source: 
Wiley Online Library

Headaches can significantly impact quality of life after aneurysm treatment. Magalhães JE et al. (Headache, June 2013) performed a 4-month prospective cohort study comparing headaches in aneurysm patients after surgical clipping or endovascular coiling using the International Classification of Headache...

Anti-Seizure Prophylaxis Does Not Prevent Seizures After Aneurysmal SAH

July 10, 2013
By: 
William J. Mack, MD
Source: 
http://www.sciencedirect.com/science/article/pii/S187887501200900X

Seizures are a well-recognized occurrence after aneurysmal subarachnoid hemorrhage (aSAH). However, incidence rates vary within the reported literature and controversy exists regarding the utility of prophylactic antiepileptic drug (AED) administration. In the May/June 2013 issue of World Neurosurgery, Raper and...

The Barrow Ruptured Aneurysm Trial: 3-Year Results

July 10, 2013
By: 
Stacey Quintero Wolfe, MD
Source: 
Journal of Neurosurgery

The 3-year results of the Barrow Ruptured Aneurysm Trial (BRAT), an intention-to-treat study comparing safety and efficacy of microsurgical clip occlusion versus endovascular coil embolization for aSAH patients, were reported in J. Neurosurgery (July 2013). Secondary analyses included outcome based...

Clazosentan Reduced Vasospasm-Related Morbidity but Did Not Improve aSAH Neurological Outcomes

July 10, 2013
By: 
Yin C. Hu, MD
Source: 
Journal of Neurosurgery

Cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhages (aSAH) causes significant cause of morbidity and mortality. Clazosentan is an endothelin receptor antagonist that inhibits endothelin-mediated vasoconstriction, and is being tested clinically for preventing vasospasm. A meta-analysis by Shen et al (J....

Pages